Sevelamer carbonate markedly reduces levothyroxine absorption

Endocrine, Metabolic and Immune Disorders - Drug Targets

Volumn 14, Issue 3, 2014, Pages 206-209

  Iovino, Michele ^a   Iovine, Nicola ^a   Petrosino, Alfanso ^a   Giagulli, Vito A ^b   Licchelli, Brunella ^b   Guastamacchia, Edoardo ^b   Triggiani, Vincenzo ^b  

^a ASL Eboli   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Dialysis; Hyperphosphataemia; Hypothyroidism; Intestinal absorption; Levothyroxine; Phosphate binder; Sevelamer carbonate

Indexed keywords

CYCLOPHOSPHAMIDE; LEVOTHYROXINE; LIOTHYRONINE; PREDNISONE; SEVELAMER CARBONATE; THYROTROPIN; THYROXINE;

ADULT; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG ABSORPTION; DRUG DOSE INCREASE; EUTHYROIDISM; FATIGUE; FEMALE; FOLLOW UP; GLOMERULONEPHRITIS; HASHIMOTO DISEASE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; MYXEDEMA; PLASMAPHERESIS; RENAL REPLACEMENT THERAPY; SOMNOLENCE;

EID: 84924294314     PISSN: 18715303     EISSN: 22123873     Source Type: Journal    
DOI: 10.2174/1871530314666140902151804     Document Type: Article

References (48)

1. Campbell, N.R.; Hasinoff, B.B.; Stalts, H.; Rao, B. and Wong, N.C. (1992) Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann. Intern. Med., 117(12), 1010-1013.
2. Shakir, K.M.; Chute, J.P.; Aprill, B.S. and Lazarus, A.A. (1997) Ferrous sulfate-induced increase in requirement for thyroxine in a patient with primary hypothyroidism. South. Med. J., 90(6), 637- 639.
3. Sherman, S.I.; Tielens, E.T. and Ladenson, P.W. (1994) Sucralfate causes malabsorption of L-thyroxine. Am. J. Med., 96(6), 531-535.
4. Havrankova, J. and Lahaie, R. (1992) Levothyroxine binding by sucralfate. Ann. Intern. Med., 117(5), 445-446.
5. Campbell, J.A.; Schmidt, B.A. and Bantle, J.P. (1994) Sucralfate and the absorption of L-thyroxine. Ann. Intern. Med., 121(2), 152.
6. Northcutt, R.C.; Stiel, J.N.; Hollifield, J.W. and Stant, E.G. Jr. (1969) The influence of cholestyramine on thyroxine absorption. JAMA., 208(10), 1857-1861.
7. Siraj, E.S.; Gupta, M.K. and Reddy, S.S. (2003) Raloxifene causing malabsorption of levothyroxine. Arch. Intern. Med., 163(11), 1367- 1370.
8. Garwood, C.L.; Van Schepen, K.A.; McDonough, R.P. and Sullivan, A.L. (2006) Increased thyroid-stimulating hormone levels associated with concomitant administration of levothyroxine and raloxifene. Pharmacotherapy., 26(6), 881-885.
9. Sachmechi, I.; Reich, D.M.; Aninyei, M.; Wibowo, F.; Gupta, G. and Kim, P.J. (2007) Effect of proton pump inhibitors on serum thyroid-stimulating hormone level in euthyroid patients treated with levothyroxine for hypothyroidism. Endocr. Pract., 13(4), 345- 349.
10. Madhava, K. and Hartley, A. (2005) Hypothyroidism in thyroid carcinoma follow-up: orlistat may inhibit the absorption of thyroxine. Clin. Oncol. (R Coll Radiol)., 17(6), 492.
11. Sperber, A.D. and Liel, Y. (1992) Evidence for interference with the intestinal absorption of levothyroxine sodium by aluminum hydroxide. Arch. Intern. Med., 152(1), 183-184.
12. Singh, N.; Singh, P.N. and Hershman, J.M. (2000) Effect of calcium carbonate on the absorption of levothyroxine. JAMA, 283(21), 2822-2825.
13. Weitzman, S.P.; Ginsburg, K.C. and Carlson, H.E. (2009) Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine. Thyroid, 19(1), 77-79.
14. Diskin, C.J.; Stokes, T.J.; Dansby, L.M.; Radcliff, L. and Carter, T.B. (2007) Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement. Int. Urol. Nephrol., 39(2), 599-602.
15. Isakova, T.; Gutiérrez, O.M.; Chang, Y.; Shah, A.; Tamez, H.; Smith, K.; Thadhani, R. and Wolf, M. (2009) Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol., 20(2), 388- 396.
16. Tonelli, M.; Pannu, N. and Manns, B. (2010) Oral phosphate binders in patients with kidney failure. N. Engl. J. Med., 362(14), 1312-1324.
17. Block, G.A.; Hulbert-Shearon, T.E.; Levin, N.W. and Port, F.K. (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis., 31(4), 607-617.
18. Block, G.A.; Klassen, P.S.; Lazarus, J.M.; Ofsthun, N.; Lowrie, E.G. and Chertow, G.M. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol., 15(8), 2208-2218.
19. Young, E.W.; Albert, J.M.; Satayathum, S.; Goodkin, D.A.; Pisoni, R.L.; Akiba, T.; Akizawa, T.; Kurokawa, K.; Bommer, J.; Piera, L. and Port, F.K. (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int., 67(3), 1179-1187.
20. Slinin, Y.; Foley, R.N. and Collins, A.J. (2005) Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J. Am. Soc. Nephrol., 16(6), 1788-1793.
21. Kalantar-Zadeh, K.; Kuwae, N.; Regidor, D.L.; Kovesdy, C.P.; Kilpatrick, R.D.; Shinaberger, C.S.; McAllister, C.J.; Budoff, M.J.; Salusky, I.B. and Kopple, J.D. (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int., 70(4), 771-780.
22. Cozzolino, M.; Rizzo, M.A.; Stucchi, A.; Cusi, D. and Gallieni, M. (2012) Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. Ther. Adv. Chronic Dis., 3(2), 59-68.
23. Delmez, J.; Block, G.; Robertson, J.; Chasan-Taber, S.; Blair, A.; Dillon, M. and Bleyer, A.J. (2007) A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin. Nephrol., 68(6), 386-391.
24. Slatopolsky, E.A.; Burke, S.K. and Dillon. M.A. (1999) RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int., 55(1), 299-307.
25. Ferramosca, E.; Burke, S.; Chasan-Taber, S.; Ratti, C.; Chertow, G.M. and Raggi, P. (2005) Potential antiatherogenic and antiinflammatory properties of sevelamer in maintenance hemodialysis patients. Am. Heart J., 149(5), 820-825.
26. Wilkes, B.M.; Reiner, D.; Kern, M. and Burke, S. (1998) Simultaneous lowering of serum phosphate and LDL-cholesterol by sevelamer hydrochloride (RenaGel) in dialysis patients. Clin. Nephrol., 50(6), 381-386.
27. Ketteler, M.; Rix, M.; Fan, S.; Pritchard, N.; Oestergaard, O.; Chasan- Taber, S.; Heaton, J.; Duggal, A. and Kalra, P.A. (2008) Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin. J. Am. Soc. Nephrol., 3(4), 1125-1130.
28. Pierce, D.; Hossack, S.; Poole, L.; Robinson, A.; Van Heusen, H.; Martin, P. and Smyth, M. (2011) The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol. Nephrol. Dial. Transplant., 26(5), 1615-1621.
29. Fleuren, H.W.; Kho, Y.; Schuurmans, M.M. and Vollaard, E.J. (2005) Drug interaction between sevelamer and furosemide. Nephrol. Dial. Transplant., 20(10), 2288-2289.
30. Kays, M.B.; Overholser, B.R.; Mueller, B.A.; Moe, S.M. and Sowinski, K.M. (2003) Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. Am. J. Kidney Dis., 42(6), 1253-1259.
31. Pieper, A.K.; Buhle, F.; Bauer, S.; Mai, I.; Budde, K.; Haffner, D.; Neumayer, H.H. and Querfeld, U. (2004) The effect of sevelamer on the pharmacokinetics of cyclosporin A and mycophenolate mofetil after renal transplantation. Nephrol. Dial. Transplant., 19(10), 2630-2633.
32. Merkle, M.; Wornle, M. and Rupprecht, H.D. (2005) The effect of sevelamer on tacrolimus target levels. Transplantation., 80(5), 707.
33. No authors listed. (2009) Sevelamer reduces the efficacy of many other drugs. Prescrire Int., 18(102), 164-165.
34. Arnadottir, M. and Johannesson. A.J. (2008) Phosphate binders and timing of levothyroxine administration. Nephrol. Dial. Transplant., 23(1), 420.
35. John-Kalarickal, J.; Pearlman, G. and Carlson, H.E. (2007) New medications which decrease levothyroxine absorption. Thyroid, 17(8), 763-765.
36. Benvenga, S.; Bartolone, L.; Squadrito, S.; Lo Giudice, F. and Trimarchi, F. (1995) Delayed intestinal absorption of levothyroxine. Thyroid, 5(4), 249-253.
37. Wenzel, K.W. and Kirschsieper, H.E. (1977) Aspects of the absorption of oral L-thyroxine in normal man. Metabolism, 26(1), 1-8.
38. Benvenga, S.; Bartolone, L.; Pappalardo, M.A.; Russo, A.; Lapa, D.; Giorgianni, G.; Saraceno, G. and Trimarchi, F. (2008) Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid, 18(3), 293-301.
39. Liel, Y.; Harman-Boehm, I. and Shany, S. (1996) Evidence for a clinically important adverse effect of fiber-enriched diet on the bioavailability of levothyroxine in adult hypothyroid patients. J. Clin. Endocrinol. Metab., 81(2), 857-859.
40. Chiu, A.C. and Sherman, S.I. (1998) Effects of pharmacological fiber supplements on levothyroxine absorption. Thyroid., 8(8), 667- 671.
41. Centanni, M.; Gargano, L.; Canettieri, G.; Viceconti, N.; Franchi, A.; Delle Fave, G. and Annibale, B. (2006) Thyroxine in goiter, Helicobacter pylori infection, and chronic gastritis. N. Engl. J. Med., 354(17), 1787-1795.
42. Muñoz-Torres, M.; Varsavsky, M. and Alonso, G. (2006) Lactose intolerance revealed by severe resistance to treatment with levothyroxine. Thyroid, 16(11), 1171-1173.
43. McDermott, J.H.; Coss, A. and Walsh, C.H. (2005) Celiac disease presenting as resistant hypothyroidism. Thyroid, 15(4), 386-388.
44. Azizi, F.; Belur, R. and Albano, J. (1979) Malabsorption of thyroid hormones after jejunoileal bypass for obesity. Ann. Intern. Med., 90(6), 941-942.
45. Bevan, J.S. and Munro, J.F. (1986) Thyroxine malabsorption following intestinal bypass surgery. Int. J. Obes., 10(3), 245-246.
46. Mersebach, H.; Rasmussen, A.K.; Kirkegaard, L. and Feldt- Rasmussen, U. (1999) Intestinal adsorption of levothyroxine by antacids and laxatives: case stories and in vitro experiments. Pharmacol. Toxicol., 84(3), 107-109.
47. Phillips, W.A.; Schultz, J.R. and Stafford, W.W. (1974) Effects of colestipol hydrochloride on drug absorption in the rat. I. Aspirin, Lthyroxine, phenobarbital, cortisone, and sulfadiazine. J. Pharm. Sci., 63(7), 1097-1103.
48. Ananthakrishnan, S.; Braverman, L.E.; Levin, R.M.; Magnani, B. and Pearce, E.N. (2008) The effect of famotidine, esomeprazole, and ezetimibe on levothyroxine absorption. Thyroid, 18(5), 493-498.